Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expansion Is Opening New Pathways For Strategic Investment
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast: What Market Value Is Expected By 2030?
Over recent years, the market size for therapeutics targeting Duchenne muscular dystrophy (DMD) has experienced exponential expansion. It is projected to increase from $16.38 billion in 2025 to $21.43 billion in 2026, representing a compound annual growth rate (CAGR) of 30.8%. This growth during the historic period has been driven by several factors, including a higher prevalence of Duchenne muscular dystrophy, heightened awareness among healthcare professionals, the launch of early-stage clinical trials, an increased uptake of physiotherapy and supportive care measures, and government incentives provided for rare disease treatments.
The duchenne muscular dystrophy (dmd) therapeutics market is projected to experience explosive expansion over the coming years. By 2030, it is anticipated to reach $62.13 billion, driven by a compound annual growth rate (CAGR) of 30.5%. This forecasted growth is fueled by progress in gene therapy, heightened funding for precision medicine, the incorporation of technology into patient monitoring, the scaling up of biologics production, and stronger partnerships between pharmaceutical and biotechnology firms. Key developments shaping the forecast period include the rise of personalized therapies, breakthroughs in gene editing and gene therapy, the emergence of innovative drug delivery methods, growth in the orphan drug sector, and a shift toward more patient-focused care models.
Download A Free Sample Report For Comprehensive Market Insights:
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Demand Drivers: What Is Fueling Industry Growth?
The Duchenne muscular dystrophy (DMD) therapeutics market is anticipated to experience growth driven by the increasing volume of clinical trials. These trials, which involve human participants, are designed to assess the safety, efficacy, and possible advantages of novel medical treatments, interventions, or pharmaceuticals. A surge in clinical trial activity is fueled by the mounting need for innovative solutions to fill gaps in current medical care. Within this context, Duchenne muscular dystrophy (DMD) therapeutics undergo rigorous testing to determine their effectiveness in slowing disease advancement and enhancing muscle performance in affected individuals. To illustrate, according to an April 2025 report from the US-based National Library of Medicine (NLM), a government agency, there were 27,751 interventional clinical trials launched during 2023. Consequently, the rising number of clinical trials is set to propel the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market.
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmentation And Category Breakdown
The duchenne muscular dystrophy (dmd) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Innovation Trends: Which Developments Are Transforming The Industry?
Leading players within the Duchenne muscular dystrophy (DMD) therapeutics sector are integrating novel technologies to boost treatment effectiveness and accessibility for patients while securing their market foothold. For example, in July 2023, Bit Bio Ltd., a synthetic biology company headquartered in the UK, unveiled disease model products aimed at advancing DMD therapies. These models, designated ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, consist of human skeletal myocytes featuring engineered deletions in the dystrophin protein gene. Derived from induced pluripotent stem cells (iPSCs) through reprogramming, Bit Bio’s offerings deliver a reliable and expandable supply of human cells for research, overcoming issues linked to primary cell variability and sourcing. Such models facilitate DMD treatment development by shedding light on disease mechanisms and possible therapeutic approaches. This innovation has the potential to expedite efforts by researchers striving to create effective DMD remedies.
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Analysis Of Major Industry Participants
Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Exonics Therapeutics Inc., Wave Life Sciences Ltd., MeiraGTx Holdings plc, Editas Medicine Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc, CRISPR Therapeutics AG, Akouos Inc., Audentes Therapeutics Inc., Stoke Therapeutics Inc., Astellas Pharma Inc., Translate Bio Inc., Ultragenyx Pharmaceutical Inc.
Access The Complete Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report:
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the DMD therapeutics market in 2025. The regions covered in the duchenne muscular dystrophy (dmd) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
